AGR2 and neoplasm: To investigate how AGR2 orchestrated the crizotinib sensitivity, we performed GSEA pathway enrichment analyses of RNA-seq and proteomics data on three BPHs (BPH1, BPH2, BPH5) and three tumor (GS6-2, GS7-8, GS9-4) primary cells that displayed the most noticeably varied crizotinib susceptibility and AGR2 expression levels (Fig. 6b).